Following the triumph of sorafenib, several targeted agents, such as sunitinib [8] and bevacizumab [9], which exhibit antitumor activity by inhibiting the vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) pathway and/or the platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) pathway, were also found to be effective against HCC. Here, VEGFA is linked to hepatocellular carcinoma.